Continuous versus bolus infusion of doxorubicin in children with ALL: Long-term cardiac outcomes

Pediatrics

Volumn 130, Issue 6, 2012, Pages 1003-1011

  Lipshultz, Steven E ^a,b   Miller, Tracie L ^a,b   Lipsitz, Stuart R ^c   Neuberg, Donna S ^d   Dahlberg, Suzanne E ^d   Colan, Steven D ^e   Silverman, Lewis B ^e,f   Henkel, Jacqueline M ^a   Franco, Vivian I ^a   Cushman, Laura L ^a   Asselin, Barbara L ^g   Clavell, Luis A ^h   Athale, Uma ⁱ   Michon, Bruno ^j   Laverdière, Caroline ^k   Schorin, Marshall A ^l   Larsen, Eric ^m   Usmani, Naheed ⁿ   Sallan, Stephen E ^e,f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^h San Jorge Children's Hospital   (Puerto Rico)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j LAVAL UNIVERSITY   (Canada)

^k UNIVERSITY OF MONTREAL   (Canada)

^l INOVA FAIRFAX HOSPITAL FOR CHILDREN   (United States)

^m Maine Children's Cancer Program Portland   (United States)

ⁿ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

more..

Author keywords

Anthracycline; Cardiotoxicity; Doxorubicin; Leukemia; Pediatrics

Indexed keywords

DOXORUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BOLUS INJECTION; CANCER REGISTRY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; FEMALE; HEART PROTECTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; TREATMENT DURATION;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; CANCER CARE FACILITIES; CARDIOMYOPATHIES; CARDIOTOXINS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; UNITED STATES; VENTRICULAR FUNCTION, LEFT;

EID: 84870555288     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0727     Document Type: Article

References (46)

1. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324(12):808-815
2. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332(26):1738-1743
3. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351(2):145-153 (Pubitemid 38886649)
4. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629-2636 (Pubitemid 46179451)
5. Möller TR, Garwicz S, Barlow L, et al Association of the Nordic Cancer Registries; Nordic Society for Pediatric Hematology and Oncology. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol. 2001;19(13):3173-3181 (Pubitemid 32591433)
6. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606
7. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality following childhood cancer. J Clin Oncol. 2010;28(8):1308-1315
8. Reulen RC, Winter DL, Frobisher C, et al British Childhood Cancer Survivor Study Steering Group. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304(2):172-179
9. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15(4):1544-1552 (Pubitemid 27167391)
10. Oeffinger KC, Mertens AC, Sklar CA, et al Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572-1582 (Pubitemid 44547808)
11. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2328-2338
12. Levitt G, Anazodo A, Burch M, Bunch K. Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? Eur J Cancer. 2009;45(17):3027-3034
13. Lipshultz SE, Lipsitz SR, Kutok J, et al. Impact of HFE mutations on cardiac status in survivors of childhood high-risk ALL: Dana-Farber Cancer Institute Childhood ALL 05-159. J Clin Oncol. 2011;29(suppl):abstr 9508
14. Visscher H, Ross CJ, Rassekh SR, et al Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30(13):1422-1428
15. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16(2):545-550 (Pubitemid 28135597)
16. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131(5):561-578 (Pubitemid 43899624)
17. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer. 1991;68(6):1221-1229
18. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96(2):133-139 (Pubitemid 12172323)
19. Synold TW, Doroshow JH. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion. J Infus Chemother. 1996;6(2):69-73
20. van Dalen EC, Raphaël MF, Caron HN, Kremer LC. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev. 2011;(1):CD006647
21. Legha SS, Benjamin RS, Mackay B, et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer. 1982;49(9):1762-1766 (Pubitemid 12153443)
22. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 1989;63(1):37-45 (Pubitemid 19031978)
23. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer. 1990;65(4):870-873 (Pubitemid 20063487)
24. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol. 2002;20(6):1677-1682 (Pubitemid 34260550)
25. Gupta M, Steinherz PG, Cheung NK, Steinherz L. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol. 2003;40(6):343-347 (Pubitemid 36514435)
26. van Dalen EC, van der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009; (4):CD005008
27. Berrak SG, Ewer MS, Jaffe N, et al. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep. 2001;8(3):611-614 (Pubitemid 33758463)
28. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-1218 (Pubitemid 32183741)
29. Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010;24(2):320-334
30. Lipshultz SE, Easley KA, Orav EJ, et al. Reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function: the prospective P(2)C(2) HIV study. Circulation. 2001;104(3):310-316 (Pubitemid 32666953)
31. Lopez L, Colan SD, Frommelt PC, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the pediatric measurements writing group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr. 2010;23(5):465-495, quiz 576-577
32. Sluysmans T, Colan SD. Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol. 2005;99(2):445-457 (Pubitemid 41061136)
33. Lipsitz SR, Fitzmaurice GM, Ibrahim JG, Gelber R, Lipshultz S. Parameter estimation in longitudinal studies with outcome-dependent follow-up. Biometrics. 2002;58(3):621-630 (Pubitemid 35001480)
34. Weiss AJ, Metter GE, Fletcher WS, Wilson WL, Grage TB, Ramirez G. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep. 1976;60(7):813-822
35. Chlebowski RT, Paroly WS, Pugh RP, et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep. 1980;64(1):47-51 (Pubitemid 10125452)
36. Ewer MS, Jaffe N, Ried H, Zietz HA, Benjamin RS. Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med Pediatr Oncol. 1998;31(6):512-515 (Pubitemid 28535919)
37. Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer. 1993;72(10):3120-3130 (Pubitemid 23335062)
38. Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99(6):745-749 (Pubitemid 14248398)
39. Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systemic review. Health Technol Assess. 2007;11(iii):ix-x, 1-84
40. Sivaprakasam P, Gupta AA, Greenberg ML, Capra M, Nathan PC. Survival and long-term outcomes in children with hepatoblastoma treated with continuous infusion of cisplatin and doxorubicin. J Pediatr Hematol Oncol. 2011;33(6):e226-e230
41. Levitt GA, Dorup I, Sorensen K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol. 2004;124(4):463-468 (Pubitemid 38230590)
42. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950-961
43. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20(23):4517-4522 (Pubitemid 35402954)
44. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30(10):1042-1049
45. Huh WW, Jaffe N, Durand JB, Munsell MF, Herzog CE. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion. Pediatr Hematol Oncol. 2010;27(7):546-557
46. 2 HIV) Study Group. Circulation. 2000;102(13):1542-1548